Company profile
Q32 Bio Inc.
NASDAQ: QTTB · Healthcare · Biotechnology
#423 of 1,422 Healthcare companies by revenue
EA Score
72BFH 89DQ 61GM 53SS 52
v0.1 · 65/100 weight · provisional
↑ net margin, return on equity · ↓ growth stability, workforce scale
Methodology →Revenue TTM
$53.7M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
$29.8M
Employees
22
as of 2026-08-14
Market cap
$457.5M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$53.7M$53.7M2025
Net income$29.8M$29.8M2025
Operating income$16.9M$16.9M2025
Total assets$61.8M$61.8M2025
Liabilities$19.8M$19.8M2025
Equity$42.0M$42.0M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Q32 Bio Inc.’s revenue?
Q32 Bio Inc. booked $53.7M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a 55.5% net margin.
Peers · Healthcare
The Joint Corp.75B+Integrated BioPharma, Inc.67BAgios Pharmaceuticals, Inc.70BInvivyd, Inc.41DRegional Health Properties, Inc.67BApyx Medical Corporation64CNeighbors
Middlesex →Key facts
CEOJodie Pope Morrison
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: QTTB
Employees22
IPO date2018-03-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.